Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
May 01, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Open market or private sale of non-derivative or derivative security	12,945	$135.29	833,041
Jan 05, 2012	YANCOPOULOS GEORGE Director, EVP, CSO & Pres, REGN Res Labs	Director, EVP, CSO & Pres, REGN Res Labs	Form 4	Open market or private sale of non-derivative or derivative security	27,713	$58.00	833,041
Dec 30, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	86,096	$483.25	822,207
Feb 15, 2024	YANCOPOULOS GEORGE Director, Bd. Co-Chair, President & CSO	Director, Bd. Co-Chair, President & CSO	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	123,601	$953.83	801,608
Dec 13, 2017	YANCOPOULOS GEORGE Director, President & CSO	Director, President & CSO	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	195,438	$21.92	786,786
Dec 13, 2017	YANCOPOULOS GEORGE Director, President & CSO	Director, President & CSO	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	11,124	$385.08	775,662
Dec 11, 2023	YANCOPOULOS GEORGE Director, Bd. Co-Chair, President & CSO	Director, Bd. Co-Chair, President & CSO	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	25,155	--	765,327
Feb 19, 2019	YANCOPOULOS GEORGE Director, President and CSO	Director, President and CSO	Form 4	Bona fide gift	150,722	--	753,316
May 01, 2024	YANCOPOULOS GEORGE Director, Bd. Co-Chair, President & CSO	Director, Bd. Co-Chair, President & CSO	Form 4	Other acquisition or disposition	--	--	752,486
Jan 04, 2024	YANCOPOULOS GEORGE Director, Bd. Co-Chair, President & CSO	Director, Bd. Co-Chair, President & CSO	Form 4	Other acquisition or disposition	--	--	752,486

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media